Advertisement
Home »

Durvalumab Climbs the MATTERHORN of Gastric Cancer

Oct 25, 2023

REFERENCES & ADDITIONAL READING

Al-Batran S-E, Homann N, Pauligk C, et al. Lancet. 2019;393(10184):1948-1957. DOI: 10.1016/S0140-6736(18)32557-1

 

Sun JM, Shen L, Shah MA, et al. Lancet. 2021;398(10302):759-771. DOI: 10.1016/S0140-6736(21)01234-4

 

Al-Batran S-A, et al. Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study. Abstract LBA73, ESMO 2023, 20-24 October, Madrid, Spain.

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


EXPLORE MORE

Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

RELEVANT ARTICLES FOR YOU

Advertisement